328 related articles for article (PubMed ID: 22877926)
1. What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt E; Gibson D
J Inorg Biochem; 2012 Dec; 117():220-9. PubMed ID: 22877926
[TBL] [Abstract][Full Text] [Related]
2. Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands.
Deng Z; Zhu G
Curr Opin Chem Biol; 2023 Jun; 74():102303. PubMed ID: 37075513
[TBL] [Abstract][Full Text] [Related]
3. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
Babu T; Sarkar A; Karmakar S; Schmidt C; Gibson D
Inorg Chem; 2020 Apr; 59(7):5182-5193. PubMed ID: 32207294
[TBL] [Abstract][Full Text] [Related]
4. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
5. Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs.
Medrano MÁ; Álvarez-Valdés A; Perles J; Lloret-Fillol J; Muñoz-Galván S; Carnero A; Navarro-Ranninger C; Quiroga AG
Chem Commun (Camb); 2013 May; 49(42):4806-8. PubMed ID: 23591566
[TBL] [Abstract][Full Text] [Related]
6. Design and investigation of photoactivatable platinum(iv) prodrug complexes of cisplatin.
Lee VEY; Chin CF; Ang WH
Dalton Trans; 2019 Jun; 48(21):7388-7393. PubMed ID: 30957798
[TBL] [Abstract][Full Text] [Related]
7. Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs.
Yap SQ; Chin CF; Hong Thng AH; Pang YY; Ho HK; Ang WH
ChemMedChem; 2017 Feb; 12(4):300-311. PubMed ID: 28028938
[TBL] [Abstract][Full Text] [Related]
8. Cancer-Specific, Intracellular, Reductive Activation of Anticancer Pt
Reshetnikov V; Daum S; Mokhir A
Chemistry; 2017 Apr; 23(24):5678-5681. PubMed ID: 28319647
[TBL] [Abstract][Full Text] [Related]
9. Chemistry and biological activity of platinum amidine complexes.
Michelin RA; Sgarbossa P; Sbovata SM; Gandin V; Marzano C; Bertani R
ChemMedChem; 2011 Jul; 6(7):1172-83. PubMed ID: 21630470
[TBL] [Abstract][Full Text] [Related]
10. Electrodrugs: an electrochemical prodrug activation strategy.
Norman DJ; González-Fernández E; Clavadetscher J; Tucker L; Staderini M; Mount AR; Murray AF; Bradley M
Chem Commun (Camb); 2018 Aug; 54(66):9242-9245. PubMed ID: 30066701
[TBL] [Abstract][Full Text] [Related]
11. Dinuclear Pt(II)-bisphosphonate complexes: a scaffold for multinuclear or different oxidation state platinum drugs.
Piccinonna S; Margiotta N; Pacifico C; Lopalco A; Denora N; Fedi S; Corsini M; Natile G
Dalton Trans; 2012 Aug; 41(32):9689-99. PubMed ID: 22782180
[TBL] [Abstract][Full Text] [Related]
12. Facile preparation of mono-, di- and mixed-carboxylato platinum(IV) complexes for versatile anticancer prodrug design.
Zhang JZ; Bonnitcha P; Wexselblatt E; Klein AV; Najajreh Y; Gibson D; Hambley TW
Chemistry; 2013 Jan; 19(5):1672-6. PubMed ID: 23255183
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.
Xu Z; Chan HM; Li C; Wang Z; Tse MK; Tong Z; Zhu G
Inorg Chem; 2018 Jul; 57(14):8227-8235. PubMed ID: 29943979
[TBL] [Abstract][Full Text] [Related]
14. Platinum(iv) anticancer prodrugs - hypotheses and facts.
Gibson D
Dalton Trans; 2016 Aug; 45(33):12983-91. PubMed ID: 27214873
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of hypoxic and acidic tumor environments with a cobalt(III) chaperone complex.
Yamamoto N; Renfrew AK; Kim BJ; Bryce NS; Hambley TW
J Med Chem; 2012 Dec; 55(24):11013-21. PubMed ID: 23199008
[TBL] [Abstract][Full Text] [Related]
16. Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
Gibson D
J Inorg Biochem; 2021 Apr; 217():111353. PubMed ID: 33477089
[TBL] [Abstract][Full Text] [Related]
17. Stability, Reduction, and Cytotoxicity of Platinum(IV) Anticancer Prodrugs Bearing Carbamate Axial Ligands: Comparison with Their Carboxylate Analogues.
Chen S; Yao H; Zhou Q; Tse MK; Gunawan YF; Zhu G
Inorg Chem; 2020 Aug; 59(16):11676-11687. PubMed ID: 32799457
[TBL] [Abstract][Full Text] [Related]
18. Layer-by-layer assembled polypeptide capsules for platinum-based pro-drug delivery.
Zhou D; Xiao H; Meng F; Zhou S; Guo J; Li X; Jing X; Huang Y
Bioconjug Chem; 2012 Dec; 23(12):2335-43. PubMed ID: 23176570
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterization, and cytotoxicity of dinuclear platinum-bisphosphonate complexes to be used as prodrugs in the local treatment of bone tumours.
Margiotta N; Ostuni R; Gandin V; Marzano C; Piccinonna S; Natile G
Dalton Trans; 2009 Dec; (48):10904-13. PubMed ID: 20023921
[TBL] [Abstract][Full Text] [Related]
20. Cationic intermediates in oxidative addition reactions of Cl2 to [PtCl2(cis-1,4-DACH)].
Margiotta N; Ranaldo R; Intini FP; Natile G
Dalton Trans; 2011 Dec; 40(48):12877-85. PubMed ID: 22064914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
